Table 1. Clinical characteristics, complete blood examination and bone marrow analyses of CMML patients in the PREACH-M trial stratified as RAS pathway (KRAS, NRAS, PTPN11, CBL) mutant vs. wildtype.
| Variable | Total (n = 24) | RAS pathway wildtype (n = 6) | RAS pathway mutant (n = 18) | P-value |
|---|---|---|---|---|
| Gender | ||||
| Male, n (%) | 13 (54%) | 2 (15%) | 11 (85%) | 0.3572 |
| Female, n (%) | 11 (46%) | 4 (36%) | 7 (64%) | |
| Age (years) | ||||
| Mean (range) | 72 (56–86) | 73 (56−86) | 70 (56−79) | 0.1424 |
| WHO classification | ||||
| CMML-0, n (%) | 4 (17%) | 1 (17%) | 3 (17%) | 0.8215 |
| CMML-1, n (%) | 13 (54%) | 4 (67%) | 9 (50%) | |
| CMML-2, n (%) | 7 (29%) | 1 (17%) | 6 (33%) | |
| MD-CMML, n (%) | 9 (38%) | 4 (67%) | 5 (28%) | 0.1501 |
| MP-CMML, n (%) | 15 (63%) | 2 (33%) | 13 (72%) | |
| BM Blast (%) | ||||
| Mean (range) | 7.3 (1.0−17.0) | 5.3 (1.0−10.3) | 9.2 (2.0−17.0) | 0.0493 |
| WCC (×109/L) | ||||
| Mean (range) | 22.1 (4.9−103.3) | 13.8 (4.9−36.8) | 30.4 (6.9−103.3) | 0.0224 |
| Hb (g/L) | ||||
| Mean (range) | 107 (79−143) | 104 (79−124) | 109 (82−143) | 0.3426 |
| PLT (×109/L) | ||||
| Mean (range) | 82 (7−219) | 91 (7−219) | 73 (18−192) | 0.3235 |
| Neutrophils (109/L) | ||||
| Mean (range) | 11.2 (1.67−47.5) | 7.2 (1.7−23.3) | 15.2 (3.0–47.5) | 0.0329 |
| Monocytes (109/L) | ||||
| Mean (range) | 5.4 (0.7−32.8) | 3.1 (1.0−8.0) | 7.8 (0.7−32.8) | 0.0267 |
| CRP (mg/L) | ||||
| Mean (range) | 4.9 (0.6−18.9) | 5.2 (1.7−18.9) | 4.5 (0.6−17) | 0.4796 |
| Spleen craniocaudal length (cm) | ||||
| Mean (range) | 13.6 (9.8−20.6) | 12.0 (10.8−13.8) | 15.2 (9.8−20.6) | 0.0400 |
n number of patients; BM bone marrow; WCC white blood cell count; Hb haemoglobin; PLT platelet; CRP C-reactive protein; MD-CMML myelodysplastic CMML; MP-CMML myeloproliferative CMML.
Mann-Whitney test was applied to continuous and Fisher’s exact test to categorical data for statistical analysis where P<0.05 was statistically significant.
2016 WHO Classification:
(i) Based on BM blast %: CMML-0 PB <2%, BM <5%; CMML-1 PB 2–4%, BM 5–9%, CMML-2 PB>5%, BM 10–19%.
(ii) Based on WCC: MD-CMML WCC<13×109/L, MP-CMML WCC>13×109/L